127 related articles for article (PubMed ID: 1869970)
21. FDG-PET in differential diagnosis and grading of chondrosarcomas.
Aoki J; Watanabe H; Shinozaki T; Tokunaga M; Inoue T; Endo K
J Comput Assist Tomogr; 1999; 23(4):603-8. PubMed ID: 10433294
[TBL] [Abstract][Full Text] [Related]
22. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography of thyroid masses.
Adler LP; Bloom AD
Thyroid; 1993; 3(3):195-200. PubMed ID: 8257858
[TBL] [Abstract][Full Text] [Related]
24. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
Rosenfeld SS; Hoffman JM; Coleman RE; Glantz MJ; Hanson MW; Schold SC
J Nucl Med; 1992 Apr; 33(4):532-6. PubMed ID: 1552337
[TBL] [Abstract][Full Text] [Related]
25. A PET study of 18FDG uptake in soft tissue masses.
Lodge MA; Lucas JD; Marsden PK; Cronin BF; O'Doherty MJ; Smith MA
Eur J Nucl Med; 1999 Jan; 26(1):22-30. PubMed ID: 9933658
[TBL] [Abstract][Full Text] [Related]
26. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
Gritters LS; Francis IR; Zasadny KR; Wahl RL
J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone.
Lee FY; Yu J; Chang SS; Fawwaz R; Parisien MV
J Bone Joint Surg Am; 2004 Dec; 86(12):2677-85. PubMed ID: 15590853
[TBL] [Abstract][Full Text] [Related]
28. Unusually high uptake of fluoro-2-deoxy-D-glucose on PET scanning of a benign paravertebral mass.
Doss M
Thorac Cardiovasc Surg; 1997 Dec; 45(6):310-1. PubMed ID: 9477465
[TBL] [Abstract][Full Text] [Related]
29. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET.
Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Von Baer A; Kotzerke J; Reske SN
J Nucl Med; 2000 Oct; 41(10):1695-701. PubMed ID: 11038000
[TBL] [Abstract][Full Text] [Related]
30. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.
Macfarlane DJ; Cotton L; Ackermann RJ; Minn H; Ficaro EP; Shreve PD; Wahl RL
Radiology; 1995 Feb; 194(2):425-9. PubMed ID: 7824722
[TBL] [Abstract][Full Text] [Related]
31. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors.
Kole AC; Nieweg OE; Hoekstra HJ; van Horn JR; Koops HS; Vaalburg W
J Nucl Med; 1998 May; 39(5):810-5. PubMed ID: 9591581
[TBL] [Abstract][Full Text] [Related]
32. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Boland GW; Goldberg MA; Lee MJ; Mayo-Smith WW; Dixon J; McNicholas MM; Mueller PR
Radiology; 1995 Jan; 194(1):131-4. PubMed ID: 7997539
[TBL] [Abstract][Full Text] [Related]
33. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Ichiya Y; Kuwabara Y; Otsuka M; Tahara T; Yoshikai T; Fukumura T; Jingu K; Masuda K
J Nucl Med; 1991 Sep; 32(9):1655-60. PubMed ID: 1880564
[TBL] [Abstract][Full Text] [Related]
34. [Regional cerebral glucose metabolism associated with ataxic gait--an FDG-PET activation study in patients with olivopontocerebellar atrophy].
Mishina M; Senda M; Ohyama M; Ishii K; Kitamura S; Terashi A
Rinsho Shinkeigaku; 1995 Nov; 35(11):1199-204. PubMed ID: 8720328
[TBL] [Abstract][Full Text] [Related]
35. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET.
Delbeke D; Meyerowitz C; Lapidus RL; Maciunas RJ; Jennings MT; Moots PL; Kessler RM
Radiology; 1995 Apr; 195(1):47-52. PubMed ID: 7892494
[TBL] [Abstract][Full Text] [Related]
36. Fluorine-18-fluorodeoxyglucose positron emission tomography in technetium-99m-hydroxymethylenediphosphate negative bone tumors.
Sasaki M; Ichiya Y; Kuwabara Y; Otsuka M; Fukumura T; Kawai Y; Koga H; Masuda K
J Nucl Med; 1993 Feb; 34(2):288-90. PubMed ID: 8429349
[TBL] [Abstract][Full Text] [Related]
37. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.
Gupta NC; Frank AR; Dewan NA; Redepenning LS; Rothberg ML; Mailliard JA; Phalen JJ; Sunderland JJ; Frick MP
Radiology; 1992 Aug; 184(2):441-4. PubMed ID: 1620844
[TBL] [Abstract][Full Text] [Related]
38. Speech-related visualization of laryngeal muscles with fluorine-18-FDG.
Kostakoglu L; Wong JC; Barrington SF; Cronin BF; Dynes AM; Maisey MN
J Nucl Med; 1996 Nov; 37(11):1771-3. PubMed ID: 8917172
[TBL] [Abstract][Full Text] [Related]
39. FDG and L-[1-11C]-tyrosine imaging of soft-tissue tumors before and after therapy.
Kole AC; Plaat BE; Hoekstra HJ; Vaalburg W; Molenaar WM
J Nucl Med; 1999 Mar; 40(3):381-6. PubMed ID: 10086699
[TBL] [Abstract][Full Text] [Related]
40. Pretherapeutic assessment of tumour metabolism using a dual tracer PET technique.
Brunkhorst T; Boerner AR; Bergh S; Otto D; Gratz FW; Knapp WH
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1416. PubMed ID: 12271430
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
